US equities |
INTC $65.64 ▼-28.71% AMZN $237.44 ▼-2.61% MU $888.62 ▼-4.89% NVDA $206.20 ▼-3.49% SNDK $1,189.38 ▼-10.58% GOOGL $279.88 ▼-1.39% AMD $510.70 ▼-9.84% TSLA $397.18 ▼-1.52%
FinancialContent

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.535 -0.045 (-2.85%)
Delayed Quote Updated: 10:27 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens ↗
CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Provides Business Updates and 2025 Overview
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Nvidia To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >